Sugi Predict

Sugi Predict / Compounds / Alfuzosin

Alfuzosin

Alfuzosin

SCHEMBL8104069

[2H]c1c(OC([2H])([2H])[2H])c(OC([2H])([2H])[2H])c([2H])c2c(N([2H])[2H])nc(N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])N([2H])C(=O)C3CCCO3)nc12

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1D

The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1D known ✓ P25100 2/20 0.46
▸ ADRA1A known ✓ P35348 2/20 0.46
▸ ADRA1B known ✓ P35368 2/20 0.46
▸ ALDH1A1 P00352 13/20 0.46
▸ KDM4E B2RXH2 9/20 0.46
▸ HSD17B10 Q99714 8/20 0.46
▸ HPGD P15428 8/20 0.46
▸ GLA P06280 6/20 0.46
▸ GAA P10253 6/20 0.46
▸ KCNH2 Q12809 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ SLC22A1 O15245 2/20 0.46
▸ ADRA2A P08913 2/20 0.46
▸ ADRA2B P18089 2/20 0.46
▸ ADRA2C P18825 2/20 0.46
▸ ACHE P22303 2/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.33
▸ NPC1 O15118 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alfuzosin SCHEMBL8108300 0.97 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8104019 0.94 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8105975 0.92 KDM4E (0.39) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8109791 0.91 KDM4E (0.56) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8094336 0.89 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8107313 0.89 KDM4E (0.56) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8097945 0.89 KDM4E (0.42) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8094424 0.88 KDM4E (0.60) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8103438 0.87 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10HPGDGLA
Alfuzosin SCHEMBL8097990 0.85 KDM4E (0.41) ALDH1A1KDM4EHSD17B10HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039473-A1 PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS AUSPEX PHARMACEUTICALS, INC. (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039473-A1 PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS ADRB1, ADRB2, ADRB3 ADRA1D 9/4885ADRA1A 8/4885ADRA1B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.